Literature DB >> 24415876

Assessment of risk of complications in cirrhosis using portal thallium scans.

Hye-Jin Tae1, Dae-Won Jun1, Yun-Young Choi1, Min-Jung Kwak1, Min-Ho Lee1.   

Abstract

AIM: To investigate the usefulness of a novel thallium scan shunt index for assessing portosystemic shunt-related cirrhotic complications.
METHODS: We enrolled 209 chronic hepatitis B-related cirrhosis patients. After rectal thallium instillation, radioactive isotope activity in the heart and liver was measured. The ratio of radiation uptake between the heart and the liver was calculated (the shunt index). This value indicates the degree of portosystemic circulation shunting. Blood tests, serum biochemistry tests, abdominal ultrasonography, gastroscopy and examination of clinical features such as the occurrence of varices, bleeding and hepatic encephalopathy were performed. Multivariate analysis was used to identify independent risk factors for complications. We compared the cumulative incidence rates of complications during the follow-up period.
RESULTS: The thallium scan shunt index was significantly higher in the decompensated liver cirrhosis group than in the compensated liver cirrhosis group (0.91 ± 0.39 vs 0.39 ± 0.32, P < 0.001). It was also higher in the varices group, the hepatic encephalopathy group, and the variceal bleeding group than in the control group (P < 0.001). Multivariate analysis showed that the index was an independent risk factor for predicting decompensated liver cirrhosis. When the cut-off value was 0.75, the shunt index had a sensitivity of 82.6%, a specificity of 84%, a positive predictive value of 61.5%, and a negative predictive value of 94.4% in diagnosing decompensated cirrhosis. When the shunt index was greater than 0.75, there was a significant increase in the number of decompensated events.
CONCLUSION: The thallium shunt index is a good predictor of cirrhosis-related complications.

Entities:  

Keywords:  Decompensation; Liver cirrhosis; Portosystemic shunt

Mesh:

Substances:

Year:  2014        PMID: 24415876      PMCID: PMC3886013          DOI: 10.3748/wjg.v20.i1.228

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

Review 1.  Targeting portal pressure measurements: a critical reappraisal.

Authors:  Ulrich Thalheimer; Maria Mela; David Patch; Andrew K Burroughs
Journal:  Hepatology       Date:  2004-02       Impact factor: 17.425

Review 2.  The management of portal hypertension: rational basis, available treatments and future options.

Authors:  Jaime Bosch; Annalisa Berzigotti; Juan Carlos Garcia-Pagan; Juan G Abraldes
Journal:  J Hepatol       Date:  2008-02-12       Impact factor: 25.083

3.  Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis.

Authors:  Francesco Vizzutti; Umberto Arena; Roberto G Romanelli; Luigi Rega; Marco Foschi; Stefano Colagrande; Antonio Petrarca; Stefania Moscarella; Giacomo Belli; Anna Linda Zignego; Fabio Marra; Giacomo Laffi; Massimo Pinzani
Journal:  Hepatology       Date:  2007-05       Impact factor: 17.425

4.  Utilization of platelet count spleen diameter ratio in predicting the presence of esophageal varices in patients with cirrhosis.

Authors:  Elliot Schwarzenberger; Trinh Meyer; Vidushi Golla; Nicole Pena Sahdala; Albert D Min
Journal:  J Clin Gastroenterol       Date:  2010-02       Impact factor: 3.062

Review 5.  Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence.

Authors:  U Thalheimer; M Mela; D Patch; A K Burroughs
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

6.  [Usefulness of liver stiffness measurement for predicting the presence of esophageal varices in patients with liver cirrhosis].

Authors:  Hyuk Sang Jung; Yun Soo Kim; Oh Sang Kwon; Yang Suh Ku; Yu Kyung Kim; Duck Joo Choi; Ju Hyun Kim
Journal:  Korean J Hepatol       Date:  2008-09

7.  Prognostic value of thallium-201 per rectum scintigraphy in alcoholic cirrhosis.

Authors:  D Urbain; V Muls; E Makhoul; H R Ham
Journal:  J Nucl Med       Date:  1994-05       Impact factor: 10.057

8.  Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis.

Authors:  Juan Turnes; Juan Carlos Garcia-Pagan; Juan G Abraldes; Manuel Hernandez-Guerra; Alessandra Dell'Era; Jaime Bosch
Journal:  Am J Gastroenterol       Date:  2006-03       Impact factor: 10.864

9.  [Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea].

Authors:  Moon Young Kim; Soon Koo Baik; Ki Tae Suk; Change Jin Yea; Il Young Lee; Jae Woo Kim; Seung Hwan Cha; Young Ju Kim; Soon Ho Um; Kwang-Hyub Han
Journal:  Korean J Hepatol       Date:  2008-06

10.  Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.

Authors:  Thierry Poynard; Françoise Imbert-Bismut; Mona Munteanu; Djamila Messous; Robert P Myers; Dominique Thabut; Vlad Ratziu; Anne Mercadier; Yves Benhamou; Bernard Hainque
Journal:  Comp Hepatol       Date:  2004-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.